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Acute respiratory failure is the leading cause of death in 
severe coronavirus disease 2019 (COVID-19). By com-
bining rapid tissue sampling at autopsy with high dimen-
sional analyses, including measurement of immune cells, 
proteins and RNA, unparalleled insights into the mecha-
nisms of dysregulated inflammation in COVID-19 have 
been obtained [1–4]. Here we summarise some of the 
conceptual advances revealed by post-mortem studies 
of severe COVID-19, and make particular reference to 
the apparent dominance of macrophages, how this may 
relate to disease pathophysiology, and the opportunities 
for targeted therapeutic intervention.
Pulmonary immunopathology drives disease 
severity in COVID‑19
Within the lung direct viral cytotoxicity is most notable 
in epithelial cells; however, the dominant pathophysi-
ological mechanism driving severe disease appears to be 
virus-triggered immunopathology. The temporal and spa-
tial disconnect between viral detection and pulmonary 
damage—where presence of viral RNA and protein is not 
always correlated with a local or proportional immune 
response and inflammation occurs in areas devoid of 
viral presence—coupled with the mortality benefits of 
anti-inflammatory therapies (corticosteroids and Inter-
leukin 6 (IL-6) blockade), argues strongly for this [5–7].
The insights gained from multi-modal cellular analysis 
implicate specific cell types and pathways driving pulmo-
nary immunopathology, pointing to potential therapeutic 
options. Histologically, diffuse alveolar damage (DAD) is 
the common, predominant pattern identified in COVID-
19, Influenza H1N1 and SARS; however, microthrombi 
occur more frequently in COVID-19 compared with 
H1N1 (57%, 24%) [8]. Within COVID-19 lung tissue, 
monocyte-macrophage lineage cells appear particularly 
dominant and are greatly expanded in number even when 
compared to viral acute respiratory distress syndrome 
arising from influenza [3, 4]. In contrast to bacterial 
pneumonia, where neutrophils predominate and mac-
rophage expansion is less marked [3, 4], COVID-19 lungs 
show lower absolute numbers of neutrophils, especially 
in severe infection and later stages of disease (Fig. 1). [3, 
4]. Furthermore, the expanded COVID-19 macrophages 
are most frequently seen in extravascular lung tissue and 
are predominantly ‘interstitial’ rather than ‘alveolar’ in 
nature, suggesting that recruitment of monocyte-mac-
rophage lineage cells from extrapulmonary sites is pro-
moting macrophage expansion within lung tissue [1, 3]. 
In keeping with this, high genotype-inferred pulmonary 
expression of the monocyte–macrophage chemotac-
tic receptor CCR2 is associated with severe disease, and 
numerous monocyte/macrophage chemotactic factors 
are elevated in blood, bronchoalveolar lavage fluid and 
whole lung tissue in COVID-19 [4, 9, 10]. These expanded 
macrophage populations are highly activated and with 
aberrant expression of key inflammation-associated mol-
ecules, often alongside expression of genes associated 
with tissue repair and fibrogenesis [2, 11, 12]. Interest-
ingly, while epithelial cells are clearly the main viral tar-
get of SARS-CoV-2 infection, studies have reported viral 
S protein within macrophages [1, 3]. Whether this rep-
resents primary infection of macrophages, or is merely a 
consequence of macrophage engulfment of infected epi-
thelial cells, remains to be determined.
Pulmonary vascular and endothelial pathology are also 
key features of fatal COVID-19, with multiple reports of 
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thrombotic complications occurring despite anticoagu-
lation therapy [11]. Ultrastructural endothelial damage 
is prevalent with intra- and extra-cellular SARS-CoV-2 
endothelial infection reported, as well as a mononuclear-
cell vasculitis affecting the intimal layer of small and 
medium-sized pulmonary arteries, mainly comprising 
 MRP8+ monocyte-macrophage cells (and not T cells as 
reported in influenza) (Fig.  1) [1]. These observations 
connect immunopathology with endothelial disruption 
and dysfunction and is consistent with immunothrombo-
sis occurring in COVID-19 [1, 13]. Whether COVID-19 
related endothelial dysfunction and thrombi can be tar-
geted by anti-inflammatory strategies awaits clarification.
Dysregulated repair driven by macrophages in the 
lung microenvironment
Given the key roles played by macrophages in regulat-
ing tissue homeostasis and repair, the non-inflammatory 
downstream effects of aberrant macrophage activa-
tion in COVID-19 have also been investigated. Evidence 
of impaired lung regeneration at the level of alveolar 
epithelial cells is observed, with the potential for mono-
cyte/macrophage-derived interleukin 1 beta (IL-1b) 
impairing epithelial repair and aiding neutrophil recruit-
ment [2, 10]. Reduced absolute numbers of endothelial 
cells, and expanded populations of mesenchymal cells 
(particularly collagen triple helix repeat-containing pro-
tein 1  (CTHRC1+) pathological fibroblasts) have been 
noted [3, 14]. The emergence of these populations, along-
side their demonstrable close proximity to macrophages 
(with some expressing potentially pro-reparative but also 
profibrotic genes such as triggering receptor expressed 
on myeloid cells 2 (TREM2) and sphingosine-1-phos-
phate phosphatase 1 SPP1), could account for the higher 
degrees of fibrosis—considered a feature of dysfunction 
repair—noted in COVID-19 lungs [3, 4].
Extrapulmonary macrophage activation 
and mobilisation
While most studies have focussed on circulating cell 
and pulmonary abnormalities, evidence also exists 
for extrapulmonary macrophage abnormalities. Iron 
Fig. 1 Summary of key histopathological findings in COVID-19 post-mortem studies to date, correlated with changes noted in the monocyte-
macrophage compartment. DAD diffuse alveolar damage, CCL2 C–C motif chemokine ligand 2, CCR2 C–C chemokine receptor type 2, IL interleukin, 
CASP3 caspase 3, CTHRC1 collagen triple helix repeat-containing 1. Figure created with BioRender.com
laden bone marrow macrophages are frequent in severe 
COVID-19 (Fig.  1). Multiple infectious diseases are 
known to impact on iron metabolism [15], with pro-
inflammatory molecules including IL-6 and IL-1beta 
established modulators of iron handling pathways [1, 
15]. Exposure to high levels of iron also induce inflam-
matory cytokine release by macrophages and lym-
phocytes, which can set-up self-reinforcing cycles of 
immune-cell activation, with macrophage haemophago-
cytosis a prominent feature of the systemic inflamma-
tory Macrophage Activation Syndrome. Notably, haem 
ingestion also significantly impairs antimicrobial func-
tions of macrophages [15], which may influence the 
high rates of secondary infection noted in patients with 
COVID-19. The extent to which haemophagocytosis is 
a driver of the pathology seen in COVID-19 awaits for-
mal testing. Extensive abnormalities in splenic tissue are 
also described, including increased abundance of mac-
rophage colony stimulating factor (M-CSF/CSF-1), an 
important mediator of proliferation and differentiation of 
monocytes, macrophages and their precursors. Whether 
splenic monocyte-macrophages directly contribute to the 
increased expansion of these cells within pulmonary tis-
sue awaits clarification.
Potential therapeutic angles
Whether targeted manipulation of monocyte/mac-
rophage pathways will lead to patient benefits awaits clin-
ical trials, but given the multiple studies implicating these 
cells as potentially causal in severe disease, this supports 
prioritising the testing of macrophage-targeting agents. 
Several approaches are possible, including macrophage 
ablation via interfering with growth factor signalling (e.g. 
anti GM-CSF or blockade of CSF1R), attenuating mono-
cyte/macrophage recruitment and expansion (e.g. target-
ing CCL2/CCR2 signalling) or targeting factors liberated 
from highly activated pro-inflammatory macrophages 
(e.g. IL-1 blockers) (Fig. 1).
Conclusions and future perspectives
Although we must approach findings from post-mortem 
studies with caution, given that they are by definition 
obtained from patients who have not survived, multi-
modal in-vivo investigations support these findings being 
generalisable to patients with severe disease. The implica-
tions of the findings of post-mortem studies for intensive 
care clinicians are several. First, they provide key data 
for the identification and trialling of targeted therapeu-
tics, and provide confidence in the trial results of proven 
therapies. Second, they indicate where, in the absence of 
COVID-19 specific trials indicating differently, we can 
apply knowledge from other related diseases, such as the 
evidence-based management of acute respiratory distress 
syndrome (ARDS) and sepsis. Third, the approaches 
taken to investigate SARS-CoV-2 infection serves as a 
platform to address critical knowledge gaps in the man-
agement and treatment of many different critical illnesses 
and illustrate the value of post-mortem examinations, 
encouraging restoration of the prominence of this tech-
nique to inform both clinical practice and research.
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